Citius Pharmaceuticals Stock Z Score
| CTXR Stock | USD 0.13 0.04 23.53% |
Citius | Z Score |
Citius Pharmaceuticals Company Z Score Analysis
Citius Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Citius Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Citius Pharmaceuticals is extremely important. It helps to project a fair market value of Citius Stock properly, considering its historical fundamentals such as Z Score. Since Citius Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Citius Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Citius Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Citius Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Citius Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Citius Pharmaceuticals from analyzing Citius Pharmaceuticals' financial statements. These drivers represent accounts that assess Citius Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Citius Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 40.7M | 220.5M | 176.8M | 103.5M | 93.2M | 60.5M | |
| Enterprise Value | 28.2M | 151.2M | 135.7M | 77.5M | 69.8M | 45.5M |
Citius Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Citius Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Citius Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Citius Pharmaceuticals' value.| Shares | Qube Research & Technologies | 2024-06-30 | 231 K | Hightower Advisors, Llc | 2024-06-30 | 215 K | Wealth Advisory Solutions, Llc | 2024-09-30 | 201 K | Arkadios Wealth Advisors | 2024-09-30 | 200 K | Bank Of America Corp | 2024-06-30 | 159.4 K | Inspire Advisors, Llc | 2024-09-30 | 157.9 K | Point72 Asia (singapore) Pte. Ltd | 2024-09-30 | 100.5 K | Hrt Financial Llc | 2024-06-30 | 100.1 K | Miller Investment Management, Lp | 2024-09-30 | 99.6 K | Armistice Capital, Llc | 2024-09-30 | 7.3 M | Vanguard Group Inc | 2024-09-30 | 6.4 M |
Citius Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 8.2 M | ||||
| Shares Outstanding | 180.72 M | ||||
| Shares Owned By Insiders | 6.80 % | ||||
| Shares Owned By Institutions | 17.02 % | ||||
| Number Of Shares Shorted | 11.79 M | ||||
| Price To Earning | (1.34) X | ||||
| Price To Book | 0.30 X | ||||
| EBITDA | (36.73 M) | ||||
| Net Income | (32.54 M) | ||||
| Cash And Equivalents | 48.04 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 481.25 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 11.40 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (29.06 M) | ||||
| Short Ratio | 13.22 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Target Price | 4.67 | ||||
| Number Of Employees | 22 | ||||
| Beta | 1.66 | ||||
| Market Capitalization | 87.15 M | ||||
| Total Asset | 103.61 M | ||||
| Retained Earnings | (162.23 M) | ||||
| Working Capital | 28.59 M | ||||
| Current Asset | 893 K | ||||
| Current Liabilities | 5.18 M | ||||
| Net Asset | 103.61 M |
About Citius Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Citius Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.82 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.7 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.69 | GILD | Gilead Sciences | PairCorr |
| 0.63 | KZR | Kezar Life Sciences | PairCorr |
| 0.44 | VRDN | Viridian Therapeutics | PairCorr |
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.